Proteomics - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 424

[7] Fix JA, Engle K, Porter PA, Leppert PS, Selk SJ, Gardner CR, et al. Acylcarnitines:
drug absorption-enhancing agents in the gastrointestinal tract. Am J Physiol 1986;
251:G332-40.
[8] Hiwada KT, Kokubu T, Murakami E, Muneta S, Morisawa Y, Yabe Y, et al. A highly
potent and long acting oral inhibitor of human renin. Hypertension 1988;11:708-12.
[9] Nakanishi K, Saitoh H, Masada M, Tatematsu A, Nadai T. Mechanism of the enhance-
ment of rectal permeability of drugs by nonsteroidal antiinflammatory drugs. Chem
Pharm Bull 1984;32:3187-93.
[10] Lieberman J. Heat lability of alpha anti-trypsin variants. Chest 1973;64:579-84.
[11] Travis J, Owen M, George P, Carrell R, Rosenberg S, Hallewell RA, et al. Isolation and
properties of recombinant DNA produced variants of human alpha 1-proteinase inhibitor.
J Biol Chem 1985;260:4384-9.
[12] Falcoff R. Some properties of virus and immune-induced human lymphocyte interferons.
J Gen Virol 1972;16:251-3.
[13] Gekko K, Timasheff SN. Mechanism of protein stabilization by glycerol: preferential
hydration in glycerol-water mixtures. Biochemistry 1981;20:4667-776.
[14] Arakawa T, Timasheff SN. Stabilization of protein structure by sugars. Biochemistry
1982;21:6536-44.
[15] Lougheed WD, Woulfe-Flanagan H, Clement JR, Albisser AM. Insulin aggregation in
artificial delivery systems. Diabetologia 1980;19:1-9.
[16] Jeffrey PD. Self-association of des-(B26-B30)-insulin. The effect of Ca 2 and some other
divalent cations. Biol Chem Hoppe-Seyler 1986;367:363-9.
[17] Lougheed WD, Albisser AM, Martindale HM, Chow JC, Clement JR. Physical stability
of insulin formulations. Diabetes 1983;32:424-32.
[18] Sato S, Jeong SY, McRea JC, Kim SW. Self-regulating insulin delivery systems. II
in vitro studies. J Controlled Release 1984;1:67-77.
[19] Bringer J, Heldt A, Grodsky GM. Prevention of insulin aggregation by dicarboxylic
amino acids during prolonged infusion. Diabetes 1981;30:83-5.
[20] Massey EH, Sheliga TA. Development of aggregation resistant insulin formulations.
Pharm Res 1986;3:26-7.
[21] Yphantis DA, Arakawa T. Sedimentation equilibrium measurements of recombinant
DNA derived human interferon gamma. Biochemistry 1987;26:5422-7.
[22] Macritchie F, Owens NF. Interfacial coagulation of proteins. J Colloid Interface Sci
1969;29:66-71.
[23] Kline DF, Hanes J, Langer R. Adjuvant-active polymeric microparticulate vaccine-delivery
systems. In: Cohen S, Bernstein H, editors. Microparticulate systems for the delivery of
proteins and vaccines. New York, NY: Marcel Dekker; 1996. p. 349-80.
[24] Kaneko Y, Sakai K, Kikuchi A, Yoshida R, Sakurai Y, Okano T. Influence of freely
mobile grafted chain length on dynamic properties of comb-type grafted poly ( N -isopro-
pylacrylamide) hydrogels. Macromolecules 1995;28:7717-23.
[25] Sershen SR, Westcott SL, Halas NJ, West NJ. Temperature sensitive polymer-
nanoshell composites for photothermally modulated drug delivery. J Biomed Mater Res
2000;51:293-8.
[26] Gutowska A, Bark JS, Kwon IC, Bae YH, Kim SW. Squeezing hydrogels for controlled
oral drug delivery. J Controlled Release 1997;48:141-8.
[27] Ahmed A, Bonner C, Desai TA. Bioadhesive microdevices for drug delivery: a feasibility
study. Biomed Microdevices 2001;3:89-96.
[28] Saslawski O, Weigarten C, Beniot JP, Couvereur P. Magnetically responsive microspheres
for pulsed delivery of insulin. Life Sci 1988;42:1521-8.